Strong CAS-led growth supports FY27 acceleration, but tariffs, TAVR softness, and MiniMed timing constrain earnings visibility.
| Quarter | Q4 FY26 |
|---|---|
| Call date | 2026-06-04 |
| Length | 64 minutes |
| EPS | $1.55 |
| EPS consensus | $1.54 |
| Revenue | $9.8B |
| Revenue consensus | $9.6B |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q1 FY27 · Q1 FY26
Read the full Q4 FY26 earnings call transcript
All MDT earnings · Back to MDT overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.